Allocation of patients to treatment groups in a controlled clinical study.

PubWeight™: 5.25‹?› | Rank: Top 1%

🔗 View Article (PMC 2009630)

Published in Br J Cancer on May 01, 1978


S J White, L S Freedman

Articles citing this

Do u smoke after txt? Results of a randomised trial of smoking cessation using mobile phone text messaging. Tob Control (2005) 8.56

Minimisation: the platinum standard for trials?. Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ (1998) 7.31

Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol (2009) 5.69

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J (2013) 4.87

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81

Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer (2008) 3.68

ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ (1998) 2.73

Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol (2004) 2.55

The Resources for Enhancing Alzheimer's Caregiver Health (REACH): project design and baseline characteristics. Psychol Aging (2003) 2.36

Randomised controlled trial of rehabilitation in chronic respiratory disability. Thorax (1981) 1.93

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol (2014) 1.70

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol (2015) 1.63

Current issues in the design and interpretation of clinical trials. Br Med J (Clin Res Ed) (1985) 1.49

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol (2012) 1.46

Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol (1982) 1.23

Psychological changes during a controlled trial of rehabilitation in chronic respiratory disability. Thorax (1982) 1.04

The MRC CRASH Trial: study design, baseline data, and outcome in 1000 randomised patients in the pilot phase. Emerg Med J (2002) 1.03

How does computer-aided diagnosis improve the management of acute abdominal pain? Ann R Coll Surg Engl (1992) 1.02

Practical experience of randomization in cancer trials: an international survey. Br J Cancer (1982) 0.99

A pilot randomized controlled trial of Dialectical Behavior Therapy with and without the Dialectical Behavior Therapy Prolonged Exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behav Res Ther (2014) 0.97

Use of beta 2 agonists in asthma: much ado about nothing? Adverse effects are not proved. BMJ (1994) 0.97

Overcoming barriers to disseminating exposure therapies for anxiety disorders: a pilot randomized controlled trial of training methods. J Anxiety Disord (2011) 0.94

Exposing clinicians to exposure: a randomized controlled dissemination trial of exposure therapy for anxiety disorders. Behav Ther (2014) 0.90

Use of and reactions to a tailored CD-ROM designed to enhance oncologist-patient communication: the SCOPE trial intervention. Patient Educ Couns (2009) 0.90

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst (2015) 0.90

Predicting adoption of exposure therapy in a randomized controlled dissemination trial. J Anxiety Disord (2013) 0.89

Light treatment for neuropsychiatric behaviors in Alzheimer's disease. West J Nurs Res (2007) 0.84

Investigating the relationship between predictability and imbalance in minimisation: a simulation study. Trials (2013) 0.79

A Collaborative Paradigm for Improving Management of Sleep Disorders in Primary Care: A Randomized Clinical Trial. Sleep (2016) 0.79

Dialectical behavior therapy and domains of functioning over two years. Behav Res Ther (2015) 0.76

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol (2017) 0.75

Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. J Neurol Neurosurg Psychiatry (1996) 0.75

Articles by these authors

Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol (2001) 11.17

Breast cancer clusters in the northeast United States: a geographic analysis. Am J Epidemiol (1997) 5.73

Tables of the number of patients required in clinical trials using the logrank test. Stat Med (1983) 5.34

On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics (1976) 3.82

Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res (1978) 3.51

Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst (1996) 2.98

Implications of a new dietary measurement error model for estimation of relative risk: application to four calibration studies. Am J Epidemiol (1999) 2.40

Statistical errors in papers in the British Journal of Psychiatry. Br J Psychiatry (1979) 2.38

Empirical evidence of correlated biases in dietary assessment instruments and its implications. Am J Epidemiol (2001) 2.33

Injuries sustained on "bouncy castles". BMJ (1992) 2.20

Inadvertent esophageal intubation in the field: reliance on a fool's "gold standard". Acad Emerg Med (1997) 2.07

Nine unknown rearrangements in 16p13.3 and 11p15.4 causing alpha- and beta-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. J Med Genet (2005) 1.96

A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Cancer (2001) 1.93

Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer (1979) 1.92

The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee. Stat Med (1994) 1.90

Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. J Natl Cancer Inst (1995) 1.84

Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol (1989) 1.83

A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Stat Med (1986) 1.82

Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet (1987) 1.79

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol (1996) 1.63

Interpreting precursor studies: what polyp trials tell us about large-bowel cancer. J Natl Cancer Inst (1994) 1.61

Can energy adjustment separate the effects of energy from those of specific macronutrients? Am J Epidemiol (1994) 1.56

In vitro antibacterial properties of BRL 36650, a novel 6 alpha-substituted penicillin. Antimicrob Agents Chemother (1984) 1.50

Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer (1991) 1.49

The use of a Kolmogorov--Smirnov type statistic in testing hypotheses about seasonal variation. J Epidemiol Community Health (1979) 1.49

MR of the brain using fluid-attenuated inversion recovery (FLAIR) pulse sequences. AJNR Am J Neuroradiol (1992) 1.49

Bayesian monitoring of phase II trials in cancer chemoprevention. J Clin Epidemiol (1999) 1.41

A stratified Wilcoxon-type test for trend. Stat Med (1990) 1.40

The future of prognostic factors in outcome prediction for patients with cancer. Cancer (1992) 1.39

The need for evaluation of gastroesophageal reflux in brain-damaged children referred for feeding gastrostomy. J Pediatr Surg (1981) 1.39

Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed) (1988) 1.39

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A (1997) 1.36

Stopping rules for clinical trials incorporating clinical opinion. Biometrics (1984) 1.33

Effect of starvation on the tissue composition of the small intestine in the rat. Am J Physiol (1968) 1.31

Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther (2004) 1.30

Variations in the level of reporting by hospitals to a regional cancer registry. Br J Cancer (1978) 1.29

Randomised comparative studies in the treatment of cancer in the United Kingdom: room for improvement? Lancet (1979) 1.29

Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy. Lancet (1979) 1.27

Randomized, placebo-controlled, double-blind study of low-dose oral interferon-alpha in HIV-1 antibody positive patients. J Acquir Immune Defic Syndr (1992) 1.27

An assay for dopamine-beta-hydroxylase activity in tissues and serum. Experientia (1971) 1.26

Copy number variation and mosaicism. Cytogenet Genome Res (2009) 1.20

Multivariate analysis of prognostic factors for operable rectal cancer. Lancet (1984) 1.18

Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2000) 1.17

Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol (2007) 1.17

The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev (1996) 1.15

Monitoring clinical trials: conditional or predictive power? Control Clin Trials (1986) 1.14

Interplay between design and analysis for behavioral intervention trials with community as the unit of randomization. Am J Epidemiol (1995) 1.13

A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet (2003) 1.13

An automatic registration method for frameless stereotaxy, image guided surgery, and enhanced reality visualization. IEEE Trans Med Imaging (1996) 1.11

Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review. Cancer Res (1997) 1.11

Predictive diagnosis of myotonic dystrophy with flanking microsatellite markers. J Med Genet (1991) 1.10

CTX, a Xenopus thymocyte receptor, defines a molecular family conserved throughout vertebrates. Eur J Immunol (1998) 1.10

An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer (1987) 1.10

Imaging ROMK1 inwardly rectifying ATP-sensitive K+ channel protein using atomic force microscopy. Proc Natl Acad Sci U S A (1996) 1.09

System delay in breast cancer in whites and blacks. Am J Epidemiol (1995) 1.09

Non-Hodgkin lymphoma of bone. Radiology (1980) 1.09

Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Br J Radiol (2002) 1.09

Stimulation of fibroblast proliferation and prostaglandin production by purified recombinant murine interleukin 1. Clin Immunol Immunopathol (1986) 1.09

Validation of intermediate end points in cancer research. J Natl Cancer Inst (1990) 1.07

Applying Bayesian ideas in drug development and clinical trials. Stat Med (1993) 1.07

Serum dopamine-beta-hydroxylase activity in neuroblastoma. N Engl J Med (1972) 1.05

Pneumatosis intestinalis in dermatomyositis. Br J Radiol (1980) 1.04

Patterns of calcification in childhood dermatomyositis. AJR Am J Roentgenol (1984) 1.04

Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis. Ann Rheum Dis (2008) 1.04

Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. J Neural Transm (Vienna) (2001) 1.03

Improving the quality of data in randomized clinical trials: the COMPACT computer package. COMPACT Steering Committee. Stat Med (1988) 1.03

A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol (1978) 1.02

Skeletal abnormalities of acrogeria, a progeroid syndrome. Skeletal Radiol (1987) 1.00

Checking for completeness of 24-h urine collection using para-amino benzoic acid not necessary in the Observing Protein and Energy Nutrition study. Eur J Clin Nutr (2013) 0.99

Energy adjustment methods for nutritional epidemiology: the effect of categorization. Am J Epidemiol (1994) 0.99

Interpretation of energy adjustment models for nutritional epidemiology. Am J Epidemiol (1993) 0.99

Changes in human serum dopamine- -hydroxylase activity with age. Nature (1972) 0.98

Sample size calculation for clinical trials: the impact of clinician beliefs. Br J Cancer (2000) 0.98

Bayesian design and analysis of two x two factorial clinical trials. Biometrics (1997) 0.98

Limitations of mortality data as a guide to comparative lung cancer incidence within an urban area. Public Health (1979) 0.97

Conditional logistic regression with sandwich estimators: application to a meta-analysis. Biometrics (1998) 0.97

Genomic imbalances in mental retardation. J Med Genet (2004) 0.97

Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant (2010) 0.97

Measurement error and dietary intake. Adv Exp Med Biol (1998) 0.96

Accuracy and time requirements of a bar-code inventory system for controlled substances. Am J Hosp Pharm (1989) 0.95

Medication errors reduced by unit-dose. Hospitals (1973) 0.95

Methods to detect CNVs in the human genome. Cytogenet Genome Res (2009) 0.94

Assignment of a gene (NEMI) for autosomal dominant nemaline myopathy to chromosome I. Am J Hum Genet (1992) 0.94

Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation (2000) 0.93

Construction and screening of Mycobacterium paratuberculosis insertional mutant libraries. Arch Microbiol (2000) 0.93

A unified method for monitoring and analysing controlled trials. Stat Med (1994) 0.93

Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium. J Biol Chem (1996) 0.93

Effect of measurement error on energy-adjustment models in nutritional epidemiology. Am J Epidemiol (1997) 0.92

A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology (2001) 0.92

Dopamine- -hydroxylase activity in mouse neuroblastoma tumors and in cell cultures. Proc Natl Acad Sci U S A (1972) 0.92

Colonic strictures in children with cystic fibrosis. Radiology (1995) 0.92

A modified approach to estimating sample size for simple logistic regression with one continuous covariate. Stat Med (2010) 0.92

Gastrointestinal complications of gastroschisis. AJR Am J Roentgenol (1985) 0.91

Stability of propranolol hydrochloride suspension compounded from tablets. Am J Hosp Pharm (1986) 0.91

Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene (2009) 0.90

Early stopping of prevention trials when multiple outcomes are of interest: a discussion. Stat Med (1994) 0.90

Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension (2001) 0.90

An aerobic recA-, umuC-dependent pathway of spontaneous base-pair substitution mutagenesis in Escherichia coli. Mutat Res (2001) 0.90

Digital imaging with a photostimulable phosphor in the chest of newborns. Radiology (1991) 0.90